AtheroGenics releases diabetes data

AtheroGenics has released Phase III trial data showing that the patients who did not have diabetes when beginning treatment and assigned to the AGI-1067 dosage group benefited by a 63 percent reduction in progression to new onset diabetes, compared to the patients receiving placebo. Release

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.